Caution Flags Raised: MARA Rating (B++) Spots Access Risks in Merck’s $10B Verona Deal
Merck Acquires Verona Pharma for $10B – Our B++ MARA Rating Warns of Access Hurdles
Merck & Co. has agreed to acquire London-based Verona Pharma plc for an estimated $10 billion, adding Ohtuvayre® (ensifentrine) – the first inhaled dual PDE3/4 inhibitor approved in June 2024 for maintenance treatment of chronic obstructive pulmonary disease (COPD) – to its portfolio.
MARA Assessment: B++ (“Marginal”)
Under the MARA Rating framework, ensifentrine receives a B++ rating (2.53/4). While clinical trials demonstrated statistically significant improvements in lung function and exacerbation rates, the annual wholesale acquisition cost (WAC) of $35,400 may exceed commonly accepted cost-effectiveness thresholds, triggering payer and HTA concerns.
Benchmark Context:
- Score: 2.53 / 4 under our 10-domain HTA framework
- Strength: Clear clinical benefits
- Risk: Launch price and system-level impact will trigger payer scrutiny
- Benchmark: Below the Respiratory TA average (3.0) and the industry five-year norm (3.0)
Affordability and Access Concerns
ICER External Affordability Alert
The Institute for Clinical and Economic Review has issued an access and affordability alert for ensifentrine, noting that at its current price point only 0.5% of the approximately 9.1 million U.S. patients with moderate-to-severe COPD could be treated over five years without surpassing ICER’s annual budget-impact threshold of $735 million. Even if the eligible population estimate is halved, the alert warns that affordability challenges will persist.
Source: ICER Press Release.
Market-Access Risks to Watch
- Price concessions needed for prompt reimbursement
- Stronger budget-impact evidence required by payers
- Possible delays in key international markets
Key Implication
Pricing and value-communication strategies must be aligned with payer and HTA expectations from launch. Early submission of robust health economic models and real-world evidence plans will be critical to avoid restrictive reimbursement policies and ensure broad patient access.
Next Steps
To explore tailored pricing scenarios, HTA outlooks, and payer engagement frameworks for ensifentrine, contact the MARA Ratings team to request a comprehensive Deep Dive report at sales@mararating.com.
Our take: Every acquisition should include an independent HTA benchmark to avoid over-optimistic access forecasts.
Learn More
Explore 350+ independent MARA Ratings: mararating.com/mara-ratings-list.
Follow MARA Rating for unbiased HTA insights: linkedin.com/company/mara-rating-company.
#Merck #VeronaPharma #COPD #MarketAccess #HTA #PricingReimbursement